{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:21:19Z","timestamp":1787023279547,"version":"build-2736575974"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2016,2,10]],"date-time":"2016-02-10T00:00:00Z","timestamp":1455062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Bayer Healthcare Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Approximately 40% of men diagnosed with metastatic prostate cancer experience one or more skeletal-related events (SREs), defined as a pathological fracture, spinal cord compression, or surgery or radiotherapy to the bone. Accurate assessment of their effect on survival, health care resource utilization (HCRU), and cost may elucidate the value of interventions to prevent SREs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods.<\/jats:title>\n                    <jats:p>Men older than age 65 years with prostate cancer and bone metastasis diagnosed between 2004 and 2009 were identified from linked Surveillance Epidemiology and End Results\u2013Medicare records. Hazard ratios (HRs) and 95% confidence intervals (CIs) for the risk for death associated with SREs were calculated by using Cox regression. HCRU and costs (in 2013 U.S. dollars) were evaluated in a propensity score-matched cohort by using Poisson regression and Kaplan-Meier sample average estimators, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Among 3,297 men with prostate cancer metastatic to bone, 40% experienced \u22651 SRE (median follow-up, 19 months). Compared with men who remained SRE-free, men with \u22651 SRE had a twofold higher risk for death (HR, 2.29; 95% CI, 2.09\u20132.51). Pathological fracture was associated with the highest risk for death (HR, 2.77; 95% CI, 2.38\u20133.23). Among men with \u22651 SRE, emergency department visits were twice as frequent (95% CI, 1.77\u20132.28) and hospitalizations were nearly four times as frequent (95% CI, 3.20\u20134.40). The attributable cost of \u22651 SRE was $21,191 (\u22651 SRE: $72,454 [95% CI, $67,362\u2013$76,958]; SRE-free: $51,263 [95% CI, $45,439\u2013$56,100]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>Among men with prostate cancer metastatic to bone, experiencing \u22651 SRE is associated with poorer survival, increased HCRU, and increased costs. These negative effects emphasize the importance of SRE prevention in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2015-0327","type":"journal-article","created":{"date-parts":[[2016,2,10]],"date-time":"2016-02-10T23:03:46Z","timestamp":1455145426000},"page":"320-326","source":"Crossref","is-referenced-by-count":62,"title":["The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone"],"prefix":"10.1093","volume":"21","author":[{"given":"Jean A.","family":"McDougall","sequence":"first","affiliation":[{"name":"a Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Washington, USA"},{"name":"b Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aasthaa","family":"Bansal","sequence":"additional","affiliation":[{"name":"a Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Washington, USA"},{"name":"b Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo H.L.","family":"Goulart","sequence":"additional","affiliation":[{"name":"a Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Washington, USA"},{"name":"b Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannine S.","family":"McCune","sequence":"additional","affiliation":[{"name":"a Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Washington, USA"},{"name":"b Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Karnopp","sequence":"additional","affiliation":[{"name":"b Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Fedorenko","sequence":"additional","affiliation":[{"name":"b Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Greenlee","sequence":"additional","affiliation":[{"name":"b Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Valderrama","sequence":"additional","affiliation":[{"name":"c Bayer Healthcare Inc., Whippany, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean D.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"a Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Washington, USA"},{"name":"b Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Ramsey","sequence":"additional","affiliation":[{"name":"a Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Washington, USA"},{"name":"b Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,2,10]]},"reference":[{"key":"2021122703515988200_B1","volume-title":"American Cancer Society. Survival rates for prostate cancer. 2015"},{"key":"2021122703515988200_B2","volume-title":"SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute, 2013","author":"Howlader"},{"key":"2021122703515988200_B3","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients","volume":"31","author":"Bubendorf","year":"2000","journal-title":"Hum Pathol"},{"issue":"4","key":"2021122703515988200_B4","first-page":"CD006250","article-title":"Bisphosphonates for advanced prostate cancer","author":"Yuen","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122703515988200_B5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/pcan.2012.42","article-title":"Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases","volume":"16","author":"Hagiwara","year":"2013","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2021122703515988200_B6","first-page":"317","article-title":"The cost of treating skeletal-related events in patients with prostate cancer","volume":"14","author":"Lage","year":"2008","journal-title":"Am J Manag Care"},{"key":"2021122703515988200_B7","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2021122703515988200_B8","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"2021122703515988200_B9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"2021122703515988200_B10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/pcan.2011.7","article-title":"Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006","volume":"14","author":"Sathiakumar","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2021122703515988200_B11","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122703515988200_B12","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00520-008-0418-0","article-title":"Impact of skeletal complications on patients\u2019 quality of life, mobility, and functional independence","volume":"16","author":"Costa","year":"2008","journal-title":"Support Care Cancer"},{"key":"2021122703515988200_B13","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","volume":"16","author":"Weinfurt","year":"2005","journal-title":"Ann Oncol"},{"key":"2021122703515988200_B14","doi-asserted-by":"crossref","first-page":"693","DOI":"10.18553\/jmcp.2010.16.9.693","article-title":"Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer","volume":"16","author":"Barlev","year":"2010","journal-title":"J Manag Care Pharm"},{"key":"2021122703515988200_B15","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40273-013-0121-y","article-title":"The economic burden of skeletal-related events among elderly men with metastatic prostate cancer","volume":"32","author":"Jayasekera","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"2021122703515988200_B16","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/CCO.0000000000000071","article-title":"Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer","volume":"26","author":"Yong","year":"2014","journal-title":"Curr Opin Oncol"},{"key":"2021122703515988200_B17","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1748-717X-7-168","article-title":"Cost of palliative radiation to the bone for patients with bone metastases secondary to breast or prostate cancer","volume":"7","author":"Hess","year":"2012","journal-title":"Radiat Oncol"},{"key":"2021122703515988200_B18","volume-title":"Bureau of Labor Statistics. Consumer Price Index: Measuring price change for medical care in the CPI. 2015"},{"key":"2021122703515988200_B19","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2005","edition":"3rd ed."},{"key":"2021122703515988200_B20","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","article-title":"Development of a comorbidity index using physician claims data","volume":"53","author":"Klabunde","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"2021122703515988200_B21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/00031305.1985.10479383","article-title":"Constructing a control-group using multivariate matched sampling methods that incorporate the propensity score","volume":"39","author":"Rosenbaum","year":"1985","journal-title":"Am Stat"},{"key":"2021122703515988200_B22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0895-4356(96)89259-6","article-title":"Estimating the costs attributable to a disease with application to ovarian cancer","volume":"49","author":"Etzioni","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"2021122703515988200_B23","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0167-6296(98)00056-3","article-title":"On the use of survival analysis techniques to estimate medical care costs","volume":"18","author":"Etzioni","year":"1999","journal-title":"J Health Econ"},{"key":"2021122703515988200_B24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jgo.2014.03.002","article-title":"Skeletal-related events and mortality among older men with advanced prostate cancer","volume":"5","author":"Onukwugha","year":"2014","journal-title":"J Geriatr Oncol"},{"key":"2021122703515988200_B25","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00520-006-0203-x","article-title":"Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer","volume":"15","author":"DePuy","year":"2007","journal-title":"Support Care Cancer"},{"key":"2021122703515988200_B26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"2021122703515988200_B27","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol"},{"key":"2021122703515988200_B28","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2015-0327","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2015-0327","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/3\/320\/41927101\/oncolo_21_3_320.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/3\/320\/41927101\/oncolo_21_3_320.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T04:51:01Z","timestamp":1718340661000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/21\/3\/320\/6401318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,10]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,2,10]]},"published-print":{"date-parts":[[2016,3,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2015-0327","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,3,1]]},"published":{"date-parts":[[2016,2,10]]}}}